Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This probiotic combination is a multi-strain live biotherapeutic product primarily developed and marketed by Bright Dairy & Food. It consists of five specific bacterial strains: *Lactobacillus delbrueckii* subsp. *bulgaricus*, *Streptococcus thermophilus*, *Lactobacillus acidophilus*, *Bifidobacterium animalis* subsp. *lactis*, and the proprietary strain *Lactobacillus casei* LC2W. The formulation is designed to modulate the gut microbiota, enhance intestinal barrier function, and improve gastrointestinal motility. The *L. casei* LC2W strain, a key component of the mixture, has been characterized for its high acid and bile salt tolerance, as well as its ability to produce short-chain fatty acids (SCFAs) and exert anti-inflammatory effects. Clinical studies have investigated this combination for its efficacy in alleviating functional constipation and improving metabolic parameters in patients with metabolic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus bulgaricus + streptococcus thermophilus + lactobacillus acidophilus + bifidobacterium lactis + lactobacillus casei LC2W.